Your browser doesn't support javascript.
loading
Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis.
Khor, Yiu Ming; Cuddy, Sarah; Harms, Hendrik J; Kijewski, Marie F; Park, Mi-Ae; Robertson, Matthew; Hyun, Hyewon; Di Carli, Marcelo F; Bianchi, Giada; Landau, Heather; Yee, Andrew; Sanchorawala, Vaishali; Ruberg, Frederick L; Liao, Ronglih; Berk, John; Falk, Rodney H; Dorbala, Sharmila.
Afiliação
  • Khor YM; Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
  • Cuddy S; Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Harms HJ; Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
  • Kijewski MF; Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
  • Park MA; Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
  • Robertson M; Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
  • Hyun H; Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
  • Di Carli MF; Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
  • Bianchi G; Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Landau H; Division of Medical Oncology, Memorial Sloan Kettering Medical Center, New York, NY, USA.
  • Yee A; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Sanchorawala V; Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.
  • Ruberg FL; Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.
  • Liao R; Stanford University Cardiovascular Institute and Cardiovascular Medicine, Stanford Amyloid Center, Stanford, CA, USA.
  • Berk J; Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.
  • Falk RH; Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Dorbala S; Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA. sdorbala@bwh.harvard.edu.
Eur J Nucl Med Mol Imaging ; 47(8): 1998-2009, 2020 07.
Article em En | MEDLINE | ID: mdl-31807884
ABSTRACT

PURPOSE:

The clinical diagnosis of pulmonary involvement in individuals with systemic AL amyloidosis remains challenging. [18F]florbetapir imaging has previously identified AL amyloid deposits in the heart and extra-cardiac organs. The aim of this study is to determine quantitative [18F]florbetapir pulmonary kinetics to identify pulmonary involvement in individuals with systemic AL amyloidosis.

METHODS:

We prospectively enrolled 58 subjects with biopsy-proven AL amyloidosis and 9 control subjects (5 without amyloidosis and 4 with ATTR cardiac amyloidosis). Pulmonary [18F]florbetapir uptake was evaluated visually and quantified as distribution volume of specific binding (Vs) derived from compartmental analysis and simpler semiquantitative metrics of maximum standardized uptake values (SUVmax), retention index (RI), and target-to-blood ratio (TBR).

RESULTS:

On visual analysis, pulmonary tracer uptake was absent in most AL subjects (40/58, 69%); 12% (7/58) of AL subjects demonstrated intense bilateral homogeneous tracer uptake. In this group, compared to the control group, Vs (median Vs 30-fold higher, 9.79 vs. 0.26, p < 0.001), TBR (median TBR 12.0 vs. 1.71, p < 0.001), and RI (median RI 0.310 vs. 0.033, p < 0.001) were substantially higher. Notably, the AL group without visually apparent pulmonary [18F]florbetapir uptake also demonstrated a > 3-fold higher Vs compared to the control group (median 0.99 vs. 0.26, p < 0.001). Vs was independently related to left ventricular SUVmax, a marker of cardiac AL deposition, but not to ejection fraction, a marker of cardiac dysfunction. Also, intense [18F]florbetapir lung uptake was not related to [11C]acetate lung uptake, suggesting that intense [18F]florbetapir lung uptake represents AL amyloidosis rather than heart failure.

CONCLUSIONS:

[18F]florbetapir PET/CT offers the potential to noninvasively identify pulmonary AL amyloidosis, and its clinical relevance warrants further study.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Amiloidose de Cadeia Leve de Imunoglobulina Limite: Humans Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Amiloidose de Cadeia Leve de Imunoglobulina Limite: Humans Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos